Healthcare Providers Increase Availability of Preventive & Curative Services During Coronavirus Pandemic
Healthcare utilization has repeatedly been observed to decrease during the ongoing COVID-19 pandemic. Such trends are affecting the growth of the solitary fibrous tumor treatment market. Many individuals still fear contracting the novel coronavirus infection. Hence, healthcare providers should increase the availability of preventive and curative services, especially for the most vulnerable populations such as older people, children, and for people living with chronic conditions.
Stakeholders in the solitary fibrous tumor treatment market are ensuring continuity of the delivery of essential healthcare services during the pandemic. They are taking efforts to adhere to government guidelines to reorganize and maintain safe access to essential health services. Pharmaceutical companies are maintaining optimum inventory levels to ensure robust supply of life-saving therapeutics.
To know the scope of our report Get a Sample on Solitary Fibrous Tumor Treatment Market
Lack of Evidence Base for Treatment Affecting Market Growth
The solitary fibrous tumor treatment market is expected to reach US$ 59.3 Mn by 2031. However, it has been found that there is no consensus guideline on the management of solitary fibrous tumors of the pleura (SFTP) and the evidence base for treatment is limited, resulting in large variations in care. Nevertheless, stakeholders are fueling their R&D efforts to increase the availability of treatments for solitary fibrous tumor (SFT).
Pazopanib holds promising potentials for advanced solitary fibrous tumor treatment. This multikinase inhibitor helps to address translocation-associated soft tissue sarcoma. Pazopanib therapy is being associated with radiological evidence of tumor response in many patients.
Get a glimpse of the in-depth analysis through our Report Brochure
Multi-disciplinary Approach Holds Promising Potentials in Increasing Patient Outcomes
In order to increase patient outcomes, companies in the solitary fibrous tumor treatment market are increasing their research in a multi-disciplinary approach. They are mainly focusing on the identification of the hallmark NAB2-STAT6 fusion that is emerging as a foundation for future translational work to identify subtype-specific therapy for the subset of SFTs that require systematic treatments.
Surgery remains the gold standard for increasing medical outcomes in the solitary fibrous tumor treatment market. On the other hand, antiangiogenic treatment is found to be effective for unresectable disease. There is a need for translational work to understand the biology driving the differential behavior of SFT and identify more effective treatments for patients with metastatic disease.
Adoption of Adjuvant Radiation Therapy Helps Control Subtotally-resected Pleural SFTs
The solitary fibrous tumor treatment market is projected to expand at a modest CAGR of 4.5% during the forecast period. Gross tumor resection remains the preferred choice for treatment of SFT. However, risk of blood loss, location, and adhesion might not always allow for this. This has led to the adoption of the adjuvant radiation therapy to achieve local control in subtotally-resected pleural SFTs.
The varying doses of external beam radiotherapy are being delivered to patients in order to improve clinical outcomes. Healthcare providers in the solitary fibrous tumor treatment market are gaining awareness that monitoring and surveillance of patients is important for better outcomes. As such, there is a need for further work on dedifferentiated SFT, which remains poorly understood.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Since healthcare utilization has increased during the COVID-19 pandemic, telehealth services and mobile apps hold promising potentials to encourage individuals to seek treatment at professional healthcare facilities. Since SFT is a rare subtype of STS (Soft-tissue Sarcoma), stakeholders in the solitary fibrous tumor treatment market should adopt a multi-disciplinary approach to deliver optimal outcomes for patients. It has been found that antiangiogenics are active and their sequential use from first line should be considered, except for dedifferentiated SFT for which chemotherapy is an optimum option. Immunohistochemistry is known to be one of the most sensitive and specific means of diagnosing SFT and is practical & economical as well.
Solitary Fibrous Tumor Treatment Market: Overview
Solitary Fibrous Tumor Treatment: Market Drivers
Market Segmentation: Solitary Fibrous Tumor Treatment Market
Regional Overview: Solitary Fibrous Tumor Treatment Market
Major Players
Solitary Fibrous Tumor Treatment Market Snapshot
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 36.5 Mn |
|
Market Forecast Value in 2031 |
US$ 59.3 Mn |
|
Growth Rate (CAGR) |
4.5% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
The report scope includes segment analysis of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, pipeline analysis, patient population data per year and COVID-19 impact analysis. |
|
Competition Landscape |
Company profiles section includes overview, business overview, strategy & recent developments, key financials, etc. |
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Solitary Fibrous Tumor Treatment Market – Segmentation
TMR’s study on the global solitary fibrous tumor treatment market includes information divided into three segments: treatment, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global solitary fibrous tumor treatment market have been discussed in detail.
| Treatment |
|
| End-user |
|
| Region |
|
Solitary fibrous tumor treatment market is expected to reach US$ 59.3 Mn by 2031
Solitary fibrous tumor treatment market is projected to expand at a CAGR of 4.5% from 2021 to 2031
Solitary fibrous tumor treatment market is driven by improvement and new development of diagnostic procedures.
North America accounted for major share of the global solitary fibrous tumor treatment market
Key players in the global solitary fibrous tumor treatment market include Pfizer, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Bayer AG, and Novartis AG.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Solitary Fibrous Tumor Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Pipeline Analysis
5.2. COVID-19 Impact Analysis
5.3. Patients Population Data, 2018-2020
6. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
6.2.1. Surgery
6.2.2. Radiation Therapy
6.2.3. Adjuvant Chemotherapy
6.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Treatment
7. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
7.2.1. Ambulatory Surgical Centers
7.2.2. Hospitals
7.2.3. Others
7.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by End-user
8. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Region
9. North America Solitary Fibrous Tumor Treatment Market Analysis and Forecast
9.1. Introduction
9.2. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
9.2.1. Surgery
9.2.2. Radiation Therapy
9.2.3. Adjuvant Chemotherapy
9.3. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
9.3.1. Ambulatory Surgical Centers
9.3.2. Hospitals
9.3.3. Others
9.4. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Solitary Fibrous Tumor Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Solitary Fibrous Tumor Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
10.2.1. Surgery
10.2.2. Radiation Therapy
10.2.3. Adjuvant Chemotherapy
10.3. Europe Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2031
10.3.1. Ambulatory Surgical Centers
10.3.2. Hospitals
10.3.3. Others
10.4. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Solitary Fibrous Tumor Treatment Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Solitary Fibrous Tumor Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Asia Pacific Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
11.2.1. Surgery
11.2.2. Radiation Therapy
11.2.3. Adjuvant Chemotherapy
11.3. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
11.3.1. Ambulatory Surgical Centers
11.3.2. Hospitals
11.3.3. Others
11.4. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Solitary Fibrous Tumor Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Solitary Fibrous Tumor Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
12.2.1. Surgery
12.2.2. Radiation Therapy
12.2.3. Adjuvant Chemotherapy
12.3. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
12.3.1. Ambulatory Surgical Centers
12.3.2. Hospitals
12.3.3. Others
12.4. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Solitary Fibrous Tumor Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Solitary Fibrous Tumor Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
13.2.1. Surgery
13.2.2. Radiation Therapy
13.2.3. Adjuvant Chemotherapy
13.3. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2031
13.3.1. Ambulatory Surgical Centers
13.3.2. Hospitals
13.3.3. Others
13.4. Middle East & Africa Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Solitary Fibrous Tumor Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
13.5.4. Competition Landscape
13.6. Competition Landscape
13.7. Company Profiles
13.7.1. Pfizer, Inc.
13.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.1.2. Growth Strategies
13.7.1.3. SWOT Analysis
13.7.2. F. Hoffmann-La Roche Ltd.
13.7.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.2.2. Growth Strategies
13.7.2.3. SWOT Analysis
13.7.3. Eli Lilly and Company
13.7.3.1. Company Overview (HQ, Business Segments)
13.7.3.2. Growth Strategies
13.7.3.3. SWOT Analysis
13.7.4. Bayer AG
13.7.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.4.2. Growth Strategies
13.7.4.3. SWOT Analysis
13.7.5. Novartis AG
13.7.5.1. Company Overview (HQ, Business Segments)
13.7.5.2. Growth Strategies
13.7.5.3. SWOT Analysis
List of Tables
Table 01: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 03: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 07: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 10: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 13: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 15: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 18: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Solitary Fibrous Tumor Treatment Market Value Share, by Region, 2020
Figure 03: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 04: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 05: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Surgery, 2017–2031
Figure 06: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Radiation Therapy, 2017–2031
Figure 07: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Adjuvant Chemotherapy, 2017–2031
Figure 08: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 09: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 10: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 11: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Ambulatory Surgery Centers, 2017–2031
Figure 12: Global Solitary Fibrous Tumor Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 13: Global Solitary Fibrous Tumor Treatment Market Value Share Analysis, by Region, 2020 and 2031
Figure 14: Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Region, 2021–2031
Figure 15: North America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country, 2020 and 2031
Figure 17: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country, 2021–2031
Figure 18: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 19: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 20: North America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 21: North America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 22: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 24: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 25: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 26: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 27: Europe Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 28: Europe Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 29: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 31: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 32: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 33: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 34: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 35: Asia Pacific Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 36: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 38: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 40: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 41: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: Latin America Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 45: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 47: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 48: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 49: Middle East & Africa Solitary Fibrous Tumor (SFT) Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Solitary Fibrous Tumor Treatment Market Trends, 2021-2031
